Spyre Therapeutics (SYRE) Projected to Post Earnings on Thursday

Spyre Therapeutics (NASDAQ:SYRE) is anticipated to issue its Q4 2025 results before the market opens on Thursday, February 26th. Analysts expect the company to announce earnings of ($0.66) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Friday, February 27, 2026 at 4:00 PM ET.

Spyre Therapeutics Trading Up 1.8%

SYRE stock opened at $36.60 on Thursday. Spyre Therapeutics has a 1-year low of $10.91 and a 1-year high of $37.98. The firm has a market cap of $2.84 billion, a PE ratio of -16.71 and a beta of 3.15. The business’s 50-day moving average price is $33.14 and its two-hundred day moving average price is $25.01.

Insider Buying and Selling

In other news, CEO Cameron Turtle sold 15,000 shares of the stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $32.80, for a total transaction of $492,000.00. Following the completion of the transaction, the chief executive officer directly owned 657,540 shares in the company, valued at $21,567,312. This represents a 2.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Over the last quarter, insiders have sold 45,000 shares of company stock worth $1,387,500. Insiders own 15.43% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Russell Investments Group Ltd. grew its stake in Spyre Therapeutics by 2,881.7% in the third quarter. Russell Investments Group Ltd. now owns 4,234 shares of the company’s stock valued at $71,000 after purchasing an additional 4,092 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Spyre Therapeutics in the 4th quarter valued at approximately $74,000. Tower Research Capital LLC TRC grew its stake in shares of Spyre Therapeutics by 182.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,769 shares of the company’s stock valued at $86,000 after buying an additional 3,725 shares in the last quarter. Man Group plc acquired a new position in Spyre Therapeutics during the second quarter worth $162,000. Finally, Martingale Asset Management L P bought a new stake in Spyre Therapeutics during the fourth quarter worth $227,000. 80.39% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Spyre Therapeutics in a research report on Monday, December 29th. JonesTrading upgraded shares of Spyre Therapeutics from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a report on Monday, December 1st. Mizuho raised shares of Spyre Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Citigroup began coverage on shares of Spyre Therapeutics in a research report on Wednesday, December 17th. They issued a “buy” rating and a $64.00 price objective on the stock. Finally, Wall Street Zen raised shares of Spyre Therapeutics from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Spyre Therapeutics currently has an average rating of “Buy” and a consensus price target of $53.88.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of novel immunotherapies for cancer. The company leverages proprietary protein engineering and biologics design platforms to create targeted molecules intended to enhance anti-tumor immune responses and inhibit tumor growth. Its preclinical pipeline comprises multiple candidate therapies for solid tumor and hematologic oncology indications.

Established by a team with deep expertise in protein design, immunology and translational research, Spyre Therapeutics collaborates with leading academic institutions and research organizations to accelerate its discovery efforts.